Similarly, it has been reported that, in human patients, high serum COX-2 levels may correlate with EGFR mutations, and that the efficacy of combined celecoxib and gefitinib is significantly greater in NSCLC cells with EGFR mutations than in wild-type NSCLC cells [139]. Here, EGFR is linked to non-small cell lung carcinoma.